Non PCV Neovascular (Wet) Age-Related Macular Degeneration (AMD)

Aflibercept is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). Decoy receptor binding prevents VEGF-A and PIGF from binding and activating endothelial cell receptors, thereby suppressing neovascularization and slowing vision loss.

EYLEA is administered intravitreally to exert local effects in the eye. Low levels are detected in the serum following intravitreal injection. Elimination Half-life: Plasma: 5-6 days

Ocular or Periocular Infections, Active Intraocular Inflammation, Hypersensitivity.

C

Excretion in breast milk unknown/not recommended 

Ocular: Conjunctival hemorrhage (12% to 25%), eye pain (9% to 13%); 1-10%: Intraocular pressure increased (5% to 8%), cataract (7%), vitreous detachment (6%), vitreous floaters (5% to 6%), conjunctival hyperemia (4% to 5%), corneal erosion (4% to 5%), foreign body sensation (3%), lacrimation increased (3%), retinal pigment epithelium detachment (3%), blurred vision (1% to 2%), retinal pigment epithelium tear (2%).

For intravitreal injection only! Age-related macular degeneration (AMD): Intravitreal injection: 2 mg (0.05 mL) every 4 weeks for 3 months then every 8 weeks thereafter.

Store at 2℃ to 8℃; do not freeze. Store in original container prior to use; protect from light.